|
1
|
Ohga S, Nakamura K, Shioyama Y, Tatsugami
K, Sasaki T, Nonoshita T, Yoshitake T, Asai K, Hirata H, Naito S
and Honda H: Acute urinary morbidity after a permanent
125I implantation for localized prostate cancer. J
Radiat Res. 55:1178–83. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Martens C, Pond G, Webster D, McLean M,
Gillan C and Crook J: Relationship of the International Prostate
Symptom score with urinary flow studies, and catheterization rates
following 125I prostate brachytherapy. Brachytherapy.
5:9–13. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arias F, Dueñas M, Martínez E, Domínguez
MA, Illarramendi JJ, Villafranca E, Tejedor M, Molina F, Meiriño R
and Valerdi JJ: Radical chemoradiotherapy for elderly patients with
bladder carcinoma invading muscle. Cancer. 80:115–120. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Lin K, Yang Z, Han N, Quan X, Guo X
and Li C: Bladder cancer stem cells: Clonal origin and therapeutic
perspectives. Oncotarget. 8:66668–66679. 2017.PubMed/NCBI
|
|
5
|
Radford IR and Aldridge DR: Importance of
DNA damage in the induction of apoptosis by ionizing radiation:
Effect of the scid mutationand DNA ploidy on the radiosensifivity
of murine lymphoid cell lines. Int J Radiat Biol. 75:143–153. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohga S, Nakamura K, Shioyama Y, Tatsugami
K, Sasaki T, Nonoshita T, Yoshitake T, Asai K, Hirata H, et al:
Acute urinary morbidity after a permanent 125I
implantation for localized prostate cancer. J Radiat Res.
55:1178–1183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prada PJ, Hevia M, Juan G, Abascal JM, de
la Rúa A, Abascal R, Fernández J and Rodríguez R: I125 Low dose
rate brachytherapy in localized prostate cancer. Preliminary
results after 5 years. Arch Esp Urol. 58:213–226. 2005.(In
Spanish). PubMed/NCBI
|
|
8
|
Lucerna M, Pomyje J, Mechtcheriakova D,
Kadl A, Gruber F, Bilban M, Sobanov Y, Schabbauer G, Breuss J,
Wagner O, et al: Sustained expression of early growth response
protein-1 blocks angiogenesis and tumor growth. Cancer Res.
66:6708–6713. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nowak AK, Chow PKH and Findlay M: Systemic
therapy for advanced hepatocellular carcinoma: A review. Eur J
Cancer. 40:1474–1484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Ji P, Liu J, Broaddus RR, Xue F
and Zhang W: Centrosome-associated regulators of the G(2)/M
checkpoint as targets for cancer therapy. Mol Cancer. 8:82009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cao XF, He XT, Ji L, Xiao J and Lv J:
Effects of neoadjuvant radiochemotherapy on pathological staging
and prognosis for locally advanced esophageal squamous cell
carcinoma. Dis Esophagus. 22:477–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu MY, Wu XY, Li QS and Zheng RM:
Expression of Egr-1 gene and its correlation with the oncogene
proteins in non-irradiated and irradiated esophageal squamous cell
carcinoma. Dis Esophagus. 19:267–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gassmann M, Chilov D and Wenger RH:
Regulation of the hypoxia-inducible factor-1 alpha. ARNT is not
necessary for hypoxic induction of HIF-1 alpha in the nucleus. Adv
Exp Med Biol. 475:87–99. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sjöström A, Bue P, Malmstrom P and
Carlsson J: Binding of 125I after administration of
125I-EGF-dextran, 125I-EGF or 125I to human bladder cancer
spheroids. Int J Oncol. 17:559–564. 2000.PubMed/NCBI
|
|
15
|
Sjöström A, Bue P, Malmström PU, Nilsson S
and Carlsson J: Binding, internalization and degradation of
EGF-dextran conjugates in two human bladder-cancer cell lines. Int
J Cancer. 70:383–389. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mariani G, Collecchi P, Baldassarri S, Di
Luca L, Buralli S, Fontanini G, Baranowska-Kortylewicz J, Adelstein
SJ and Kassis AI: Tumor uptake and mitotic activity pattern of
5-[125I]iodo-2′- deoxyuridine after intravesical infusion in
patients with bladder cancer. J Nucl Med. 37:16–19. 1996.PubMed/NCBI
|
|
17
|
van den Abbeele AD, Tutrone RF, Berman RM,
Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ and
Kassis AI: Tumor-targeting potential of radioiodinated
iododeoxyuridine in bladder cancer. J Nucl Med. 37:315–320.
1996.PubMed/NCBI
|
|
18
|
Colpi GM, Fanciullacci F, Beretta G, Negri
L and Zanollo A: Evoked sacral potentials in subjects with true
premature ejaculation. Andrologia. 18:583–586. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xin ZC, Choi YD, Rha KH and Choi HK:
Somatosensory evoked potentials in patients with primary premature
ejaculation. J Urol. 158:451–455. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xin ZC, Chung WS, Choi YD, Seong DH, Choi
YJ and Choi HK: Penile sensitivity in patients with primary
premature ejaculation. J Urol. 156:979–981. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Smith K, Fennelly JA, Neal DE, Hall RR and
Harris AL: Characterization and quantitation of the epidermal
growth factor receptor in invasive and superficial bladder tumors.
Cancer Res. 49:5810–5815. 1989.PubMed/NCBI
|
|
22
|
Tamura K, Araki F and Ohno T: SU-F-T-46:
The effect of inter-seed attenuation and tissue composition in
prostate 125I brachytherapy dose calculations. Med Phys.
43:3471–3472. 2016. View Article : Google Scholar
|
|
23
|
Tan Q, Qin Q, Yang W, Lian B, Mo Q and Wei
C: Combination of 125I brachytherapy and chemotherapy for
unresectable recurrent breast cancer: A retrospective control
study. Medicine (Baltimore). 95:e53022016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jeon J, Shim HE, Mushtaq S, Choi MH, Park
SH, Choi DS and Jang BS: An optimized protocol for the efficient
radiolabeling of gold nanoparticles by using a
125I-labeled azide prosthetic group. J Vis Exp.
e547592016.
|
|
25
|
Jiao D, Wu G, Ren J and Han X:
Radiofrequency ablation versus 125I-seed brachytherapy
for painful metastases involving the bone. Oncotarget.
7:87523–87531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Becker S, Schlederer T, Kramer MF, Haack
M, Vrtala S, Resch Y, Lupinek C, Valenta R and Gröger M: Real-life
study for the diagnosis of house dust mite allergy - the value of
recombinant allergen-based IgE serology. Int Arch Allergy Immunol.
170:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sheikholeslami S, Nedaie HA, Sadeghi M,
Pourbeigy H, Shahzadi S, Zehtabian M, Hasani M and Meigooni AS:
Monte Carlo calculations and experimental measurements of the
TG-43U1-recommended dosimetric parameters of 125I (Model
IR-Seed2) brachytherapy source. J Appl Clin Med Phys. 17:430–441.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Asadi S, Vaez-Zadeh M, Vahidian M,
Marghchouei M and Masoudi SF: Ocular brachytherapy dosimetry for
103Pd and 125I in the presence of gold
nanoparticles: A Monte Carlo study. J Appl Clin Med Phys. 17:90–99.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sugawara A1, Nakashima J, Shigematsu N,
Kunieda E and Kubo A: Prediction of seed migration after
transperineal interstitial prostate brachytherapy with I-125 free
seeds. Brachytherapy. 8:52–56. 2009. View Article : Google Scholar : PubMed/NCBI
|
